Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
07/08/2025 18:46
Rapport Therapeutics Inc RAPP.OQ reported a quarterly adjusted loss of 75 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.70. The mean expectation of six analysts for the quarter was for a loss of 83 cents per share. Wall Street expected results to range from -94 cents to -76 cents per share. Reported revenue was zero; analysts expected zero. Rapport Therapeutics Inc's reported EPS for the quarter was a loss of 75 cents. The company reported a quarterly loss of $26.73 million. Rapport Therapeutics Inc shares had risen by 28.5% this quarter and lost 17.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Rapport Therapeutics Inc is $35.00, about 58.3% above its last closing price of $14.61 This summary was machine generated from LSEG data August 7 at 05:45 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.83 | -0.75 | Beat |
| Mar. 31 2025 | -0.76 | -0.68 | Beat |
| Dec. 31 2024 | -0.62 | -0.57 | Beat |
| Sep. 30 2024 | -0.58 | -0.50 | Beat |